Atrion Co. (NASDAQ:ATRI – Get Rating)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $620.93, but opened at $636.90. Atrion shares last traded at $616.03, with a volume of 2 shares traded.
Analyst Upgrades and Downgrades
Separately, StockNews.com downgraded shares of Atrion from a “buy” rating to a “hold” rating in a report on Tuesday, November 8th.
Atrion Stock Down 3.4 %
The business’s 50 day moving average is $603.47 and its two-hundred day moving average is $621.36. The firm has a market capitalization of $1.07 billion, a P/E ratio of 31.27 and a beta of 0.28.
Atrion Announces Dividend
Insiders Place Their Bets
In related news, CFO Jeffery Strickland sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 26th. The stock was sold at an average price of $675.00, for a total value of $675,000.00. Following the completion of the sale, the chief financial officer now owns 1,532 shares of the company’s stock, valued at approximately $1,034,100. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 22.65% of the company’s stock.
Institutional Investors Weigh In On Atrion
Several large investors have recently made changes to their positions in ATRI. HM Payson & Co. bought a new stake in Atrion during the first quarter worth approximately $26,000. Quantbot Technologies LP bought a new stake in Atrion during the third quarter worth approximately $29,000. Steward Partners Investment Advisory LLC bought a new stake in Atrion during the first quarter worth approximately $34,000. Nisa Investment Advisors LLC bought a new stake in Atrion during the first quarter worth approximately $36,000. Finally, Great West Life Assurance Co. Can bought a new stake in Atrion during the third quarter worth approximately $52,000. Institutional investors own 65.68% of the company’s stock.
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Canada, Europe, and internationally. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
- Get a free copy of the StockNews.com research report on Atrion (ATRI)
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ’s Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.